Healthcare Sales & Marketing Network News: eribulin mesylate

Searching News Database: eribulin mesylate

HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Jan 2016
FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Feb 2015
Topline Results of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint of Overall Survival in Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Nov 2010
FDA Approves Eisai’s Halaven(TM) (Eribulin Mesylate) Injection for Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Mar 2010
Eisai Submits Marketing Authorisation Application for Approval of Eribulin Mesylate in Europe, Based on Significant Overall Survival in Late Stage Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Biopharmacetuicals Onocology

HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.